Trump admin is working to cut pharma ads: Report
The Trump administration is drafting a policy that would “make it harder and more expensive” for drugmakers to advertise directly to consumers, Bloomberg News reported on Tuesday.
The policy being floated is not an outright ban but one that adds “legal and financial hurdles,” sources told Bloomberg. Pharmaceutical companies account for a huge chunk of the advertising industry.
The news sent some pharma stock nudging down, including Novo Nordisk and Eli Lilly, which currently sell wildly popular GLP-1 weight-loss drugs. It’s unclear how the policy would affect telehealth companies like Hims & Hers, which also advertise drugs to consumers but operate in a legal gray area.
The news sent some pharma stock nudging down, including Novo Nordisk and Eli Lilly, which currently sell wildly popular GLP-1 weight-loss drugs. It’s unclear how the policy would affect telehealth companies like Hims & Hers, which also advertise drugs to consumers but operate in a legal gray area.
